Lipoplatin™ Monotherapy: A Phase II Trial of Second-Line Treatment of Metastatic Non-Small-Cell Lung Cancer

References

• Rosenberg B, Van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385–386.
   PubMed Web of Science ®Google Scholar
• Ball D, Smith J, Wirth A, et al. Failure of T stage to pre-dict survival in patients with non-small cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2002; 54: 1007–1013.
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899–909.
   PubMed Web of Science ®Google Scholar
• Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002; 87: 825–833.
   PubMed Web of Science ®Google Scholar
• Boulikas T, Vougiouka M. Recent clinical trials using cis-platin, carboplatin and their combination chemotherapy drugs (Review). Oncol Rep 2004, 11: 559–595.
   PubMed Web of Science ®Google Scholar
• McKeage MJ. Comparative adverse effect profiles of plat-inum drugs. Drug Saf 1995; 13: 228–244.
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460–464.
   PubMed Web of Science ®Google Scholar
• Townsend DM, Deng M, Zhang L, et al. Metabolism of cis-platin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14: 1–10.
   PubMed Web of Science ®Google Scholar
• Humes HD. Insights into ototoxicity. Analogies to nephro-toxicity. Ann NY Ascad Sci 1999; 884: 15–18.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Martini C, Spatti G, et al. Recovering optic neuritis during systematic cisplatin and carboplatin chemother-apy. Acta Neurol Scand 1997; 96: 260–261.
   PubMed Web of Science ®Google Scholar
• Ali BH, Al Moundhri MS. Agents ameliorating or aug-menting the nephrotoxicity of cisplatin and other platinum com-pounds: a review of some recent research. Food Chem Toxicol 2006; 44: 1173–1183.
   PubMed Web of Science ®Google Scholar
• Waters JS, O'Brien ME. The case for introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer 2002; 87: 481–490.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Boulikas T, Vougiokas M, et al. Phar-macokinetics and adverse reactions of new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 2005; 13: 589–595.
   PubMed Web of Science ®Google Scholar
• Boulikas T. Low toxicity and activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12: 3–12.
   PubMed Web of Science ®Google Scholar
• Boulikas T, Stathopoulos GP, Volakakis N, et al. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005; 25: 3031–3039.
   PubMed Web of Science ®Google Scholar
• Bandak S, Goren D, Horowitz A, et al. A pharmacologi-cal studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 1990; 10: 911–920.
   Web of Science ®Google Scholar
• Devarajan P, Tarabishi R, Mishra J, et al. Low renal tox-icity of Lipoplatin compared to Cisplatin in animals. Anticancer Res 2004; 24: 2193–2200.
   PubMed Web of Science ®Google Scholar
• Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10: 1663–1682.
   PubMed Web of Science ®Google Scholar
• Jehn CF, Boulikas T, Kourvetaris, et al. Pharmacokinet-ics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 2007; 27: 471–475.
   Google Scholar
• Stathopoulos GP, Boulikas T, Vougiouka M, et al. Lipo-somial cisplatin with gemcitabine in pretreated advanced pan-creatic cancer patients: a phase I-II study. Oncol Rep 2006; 15: 1201–1204.
   PubMed Web of Science ®Google Scholar
• Minko T, Pakunlu RI, Wang Y. New generation of lipo-somial drugs of cancer. Anticancer Agents Med Clin 2006; 6: 537–552.
   PubMedGoogle Scholar
• Gormley P, Bull J, LeRoy A, et al. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 1979; 25:351.
   PubMed Web of Science ®Google Scholar
• Belt R, Himmelstein K, Patton T, et al. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1979; 63: 1515.
   PubMedGoogle Scholar
• Shepherd FA, Kancey J, Ramlau R, et al. Prospective ran-domized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–2103.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, FosseIla FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–1596.
   PubMed Web of Science ®Google Scholar
• Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cncer. Clin Ther 2005; 27: 1513–1534.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in Lung Cancer: Molecular and Clinical predictors of Outcome. N Engl J Med 2005; 353: 133–144.
   PubMed Web of Science ®Google Scholar
• White SC, Lorigan P, Margison GP, Margison JM, Mar-tin F,Thatcher N, Anderson H, Ranson M. Phase II study of SPI-77(stericallystabilised liposomal cisplatin) in advanced non-small-cell lung cancer.BJC 2006; 95: 822–828.
   PubMed Web of Science ®Google Scholar
• De Mario MD, Vogelzang NJ, Janisch L., Tonda M., Amantea MA., Pendyala L., Ratain U. A phase I study of lipo-some-formulated Cisplatin (SPI-77R) given every 3 weeks in pa-tients with advanced cancer (meeting abstract), Abstract no.883, ASCO Annual Meeting 1998.
   Google Scholar
• Harrington KJ, Lewansky CR, Northcote AB, Whittaker J., Wellbank H, Vile RG, Peters AM, Stewart JS, Phase I-II of pegylated liposomal Cisplatin (SPI- 077) in patients with inoper-able head and neck cancer. Ann Oncol. 2001; 12: 493–6.
   PubMed Web of Science ®Google Scholar